Acute kidney injury is a common problem in a clinic of critical emergency medicine, which is usually accompanied by high mortality. Ceruloplasmin is a plasma antioxidant that prevents the formation of toxic iron ion, activation of lipid peroxidation and protects the structure of lipid membranes from the damage. This enzyme is also involved in the detoxification of superoxide anions in the extracellular medium. The aim of the research is to study the changes in the levels of ceruloplasmin in blood plasma and product of lipid peroxidation malonic aldehyde (MA) in blood and kidney tissue under the conditions of mioglobinuric acute kidney injury on the background of ceruloplasmin administration. Materials and methods. The experimental studies were performed on white nonlinear rats. We modeled the acute kidney injury by intramuscular administration of 50% glycerol solution at a dose of 8 mg/kg. Ceruloplasmin was administered intraperitoneally at a dose of 7 mg/kg/day. The level of ceruloplasmin in blood plasma and the level of malonic aldehyde in blood and kidney tissue was determined 24 h, 48 h, and 72 h after glycerol administration and induction of acute kidney injury. Results and discussion. The performed experimental studies indicated a significant deterioration of the prooxidant-antioxidant balance in the blood and of kidney tissue under the conditions of acute kidney injury. At the same time, there was a decrease in antioxidant defense. The ceruloplasmin administration to rats with acute kidney injury leads to decrease in the intensity of lipoperoxidation processes, as evidenced by the parameters of malonic aldehyde in the tissue of the kidneys and blood compared to animals with a model pathological process. At the same time, an increase in the level of ceruloplasmin in blood plasma improves antioxidant defense under the condition of acute kidney injury. Conclusion. The research showed that ceruloplasmin administration in acute kidney injury decreased the intensity of free radical reactions in kidney tissue and blood and improved antioxidant protection by reducing lipid peroxidation. It also prevented the further development of destructive processes in kidneys.

Keywords: acute kidney injury, antioxidant, ceruloplasmin

Full text: PDF (Ukr) 228K

1. Arutjunjan AV, Dubinina EE, Zybina NN. Metody ocenki svobodnoradikal'nogo okislenija i antioksidantnoj sistemy organizma. Metodicheskie rekomendacii. S-Pb: IKF «Foliant», 2000. 104 s. [Russian]
2. Dombrovskij JaA, Ivanova MD. Korrekcija anemii i intoksikacii preparatami ceruloplazmina u pacientov s hronicheskoj bolezn'ju pochek. Pochki. 2014; 1 (7): 71-3. [Russian]
3. Eliseev EV, Kokoreva EG, Tregubova MV. Ceruloplazmin i rjad biologicheski aktivnyh substratov pri autotransfuzii ul'trafioletom obluchjonnoj krovi. Vestnik Cheljabinskogo gosudarstvennogo universiteta. 2014; 4 (333): 44–8. [Russian]
4. Kupchinskaja SS. Biologicheskaja i patogeneticheskaja rol' antioksidantnoj sistemy v funkcionirovanii zhivogo organizma. Tol'jattinskij medicinskij konsilium. 2014; 1-2: 56–9. [Russian]
5. Magaljas VM, Myhjejev AO, Rogovyj JuJe. Suchasni metodyky eksperymental'nyh ta klinichnyh doslidzhen' central'noi' naukovo-doslidnoi' laboratorii' BDMA. Chernivci: BDMA, 2001. 42 s. [Ukrainian]
6. Malysh IR, Zgrzheblovs'ka LV, Beshlej IA, Dvors'kyj PD. Zastosuvannja preparatu Biocerulin u kompleksi intensyvnoi' terapii' u postrazhdalyh z tjazhkoju politravmoju. Ukrai'ns'kyj zhurnal ekstremal'noi' medycyny imeni GO Mozhajeva. 2010; 11(4): 68-72. [Ukrainian]
7. Moshkov KA, Zajcev VN, Romanovskaja EV, Stefanov VE. Ceruloplazmin: vnutrimolekuljarnyj perenos jelektronov i ferroksidaznaja aktivnost'. Fundamental'nye issledovanija. 2014; 3-1: 104-8. [Russian]
8. Nechaj AV. Antyoksydant ceruloplazmin ta pidbir jogo dozy pry gostrij nyrkovij nedostatnosti v eksperymenti. Medychna himija. 2007; 9(4): 80-1. [Ukrainian]
9. Harchenko VV. Pryrodni bioantyoksydanty ta pechinka. Suchasna gastroenterologija. 2007; 6(38): 79-85. [Ukrainian]
10. Shhudrova TS, Zamors'kyj II. Vplyv organospecyfichnyh peptydiv na proteolitychnu ta fibrynolitychnu aktyvnist' u nyrkah za umov rozvytku rabdomiolitychnoi' gostroi' nyrkovoi' nedostatnosti. Visnyk Vinnyc'kogo nacional'nogo med universytetu. 2014; 18(2): 416–18. [Ukrainian]
11. Dubick MA, Barr JL, Keen CL, Atkins JL. Ceruloplasmin and hypoferremia: studies in burn and non-burn trauma patients. Antioxidants. 2015; 4: 153-69. https://www.ncbi.nlm.nih.gov/pubmed/26785343. https://www.ncbi.nlm.nih.gov/pmc/articles/4665565. https://doi.org/10.3390/antiox4010153
12. Mahajan RD, Mishra B, Singla P. Сeruloplasmin – an update. Int J of Pharmaceutical Sciences Review and Research. 2011; 9(2): 116-9.
13. Samygina VR, Sokolov AV, Bourenkov G, Petoukhov MV, Pulina MO, Zakharova ET, Vasilyev VB, Bartunik H, Svergun DI. Ceruloplasmin: macromolecular assemblies with iron containing acute phase proteins. Plos one. 2013; 8(7): e67145. https://www.ncbi.nlm.nih.gov/pubmed/23843990. https://www.ncbi.nlm.nih.gov/pmc/articles/3700992. https://doi.org/10.1371/journal.pone.0067145.
14. Vashchenko G, MacGillivray RTA. Multi-copper oxidases and human iron metabolism. Nutrients. 2013; 5: 2289–313. https://www.ncbi.nlm.nih.gov/pubmed/23807651. https://www.ncbi.nlm.nih.gov/pmc/articles/3738974. https://doi.org/10.3390/nu5072289